![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1788278
¼¼°èÀÇ Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ½ÃÀåLung Cancer Screening Software |
¼¼°èÀÇ Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2030³â±îÁö 4,050¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á
2024³â¿¡ 2,840¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2030³â¿¡´Â 4,050¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¹Ì±¹ ½ÃÀåÀº 750¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.0%·Î ¼ºÀå ¿¹Ãø
¹Ì±¹ÀÇ Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2024³â¿¡ 750¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 650¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 5.7%¿Í 5.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼´Â µ¶ÀÏÀÌ CAGR 4.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ¼¼°è ½ÃÀå - Á¶±â ¹ß°ß¡¤Áø´Ü¿¡ Çõ¸íÀ» °¡Á®¿Â´Ù
Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î°¡ Àα⸦ ²ô´Â ÀÌÀ¯´Â?
Æó¾ÏÀº Àü ¼¼°è ¾Ï °ü·Ã »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎ Áß ÇϳªÀ̸ç, ¹ß°ßÀÌ ´Ê¾îÁ® »ç¸Á·üÀÌ ³ô½À´Ï´Ù. Á¶±â Áø´ÜÀ» ÅëÇØ »ýÁ¸À²ÀÌ Å©°Ô Çâ»óµÇ¾úÀ¸¸ç, Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î´Â ¹ß°ßÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀÌ´Â Áß¿äÇÑ Åø·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¿µ»ó Áø´Ü¿¡ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)À» µµÀÔÇÏ´Â °ÍÀº ¹æ»ç¼±°ú Àü¹®ÀÇ¿Í Á¾¾ç Àü¹®Àǰ¡ Æó °áÀýÀ» º¸´Ù Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿Í ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Àå±â Èí¿¬ÀÚ µî °íÀ§Ç豺À» ´ë»óÀ¸·Î ÇÑ Á¤ºÎÀÇ ±¸»ó°ú °ËÁø ÇÁ·Î±×·¥Àº ÷´Ü °ËÁø ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î°¡ º´¿øÀÇ ¹æ»ç¼±°ú¿Í ¿ø°ÝÀÇ·á Ç÷§Æû¿¡ ÅëÇÕµÇ¸é¼ Á¶±â ¹ß°ßÀÌ ´õ¿í Ä£¼÷Çϰí È¿°úÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.
Çõ½ÅÀº Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾îÀÇ ¼º´ÉÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?
AI ±â¹Ý ¾Ë°í¸®Áò°ú µö·¯´× ¸ðµ¨ÀÇ ÅëÇÕÀ¸·Î Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾îÀÇ Á¤È®µµ°¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÀÛÀº °áÀýµµ °¨ÁöÇÏ¿© ¿µ»ó ºÐ¼®À» °ÈÇÏ¿© Áø´ÜÀÇ À§¾ç¼º ¹× À§À½¼ºÀ» °¨¼Ò½Ãŵ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý °ËÁø Ç÷§Æû°ú ¿ø°ÝÀÇ·á ÅëÇÕÀ» ÅëÇØ ƯÈ÷ ¿ø°ÝÁö³ª ÀÇ·á ¼ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼ °ËÁø ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹Ãø ºÐ¼®ÀÇ µµÀÔÀº Àǻ簡 ȯÀÚÀÇ À§Çè ¿äÀÎÀ» Æò°¡Çϰí Ãß°¡ Æò°¡¸¦ À§ÇØ °íÀ§Çè »ç·ÊÀÇ ¿ì¼±¼øÀ§¸¦ Á¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î¿Í ÀüÀÚÀǹ«±â·Ï(EHR)À» °áÇÕÇÏ¿© ¿öÅ©Ç÷οìÀÇ È¿À²¼ºÀ» ³ôÀ̰í, ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼® ¹× ÀÚµ¿ÈµÈ º¸°í¼ ÀÛ¼ºÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº?
Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¸î °¡Áö ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. Æó¾ÏÀÇ À¯º´·ü Áõ°¡¿Í Á¶±â ¹ß°ß¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁø °ÍÀÌ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ƯÈ÷ ¼±Áø±¹¿¡¼´Â Æó¾Ï °ËÁø ÇÁ·Î±×·¥À» Áö¿øÇÏ´Â Á¤ºÎ ±ÔÁ¦¿Í ÇコÄɾî Á¤Ã¥À¸·Î ÀÎÇØ Æó¾Ï °ËÁø ÇÁ·Î±×·¥ µµÀÔÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ºÐ¾ß¿¡¼ AI¿Í ÀÚµ¿ÈÀÇ È°¿ëÀÌ È®´ëµÇ°í, µðÁöÅÐ Çコ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¤±³ÇÑ ½ºÅ©¸®´× ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Å¬¶ó¿ìµå ±â¹Ý ÀÇ·á¿ë ¿µ»óó¸® Ç÷§ÆûÀÇ È®´ë¿Í ¼ÒÇÁÆ®¿þ¾î °³¹ßÀÚ¿Í ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿ÍÀÇ Çù¾÷ Áõ°¡°¡ ½ÃÀå °³¹ß¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
°úÁ¦¿Í ¹Ì·¡ ±âȸ´Â?
Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº ±× ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ³ôÀº µµÀÔ ºñ¿ë, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦, ±âÁ¸ ÇコÄɾî IT ½Ã½ºÅÛ°úÀÇ »óÈ£¿î¿ë¼º ¹®Á¦ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼öÀÛ¾÷¿¡ ÀÇÇÑ ¿µ»ó ºÐ¼®¿¡ ÀÇÁ¸ÇÏ´Â ±âÁ¸ ¿µ»óÀÇÇаú ÀÇ»çµéÀÇ ÀúÇ×µµ äÅÃÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª AI Áö¿ø Áø´ÜÀÇ ¼ö¿ë È®´ë, º¸´Ù ºñ¿ë È¿À²ÀûÀΠŬ¶ó¿ìµå ±â¹Ý ¼Ö·ç¼ÇÀÇ °³¹ß, ¹ý±Ô ÁؼöÀÇ ÁøÀüÀ¸·Î ÀÎÇØ Å« ºñÁî´Ï½º ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù. ÇâÈÄ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº AI¸¦ Ȱ¿ëÇÑ ½Ç½Ã°£ Áø´Ü, À¯ÀüÀû ¿äÀÎ ¹× »ýȰ½À°ü ¿äÀο¡ ±â¹ÝÇÑ °³ÀÎ ¸ÂÃãÇü °ËÁø ÇÁ·ÎÅäÄÝ, Æó¾Ï °ËÁø ¼ÒÇÁÆ®¿þ¾îÀÇ ¸ð¹ÙÀÏ Çコ ¿ëµµ¿¡ ´ëÇÑ ÅëÇÕÀÔ´Ï´Ù.
ºÎ¹®
´ÜÀÏ ºÎ¹®
AI ÅëÇÕ
¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.
Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°è °íÀ¯ SLM¿¡ Äõ¸® ÇÏ´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.
°ü¼¼ ¿µÇâ °è¼ö
Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Global Lung Cancer Screening Software Market to Reach US$40.5 Million by 2030
The global market for Lung Cancer Screening Software estimated at US$28.4 Million in the year 2024, is expected to reach US$40.5 Million by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030.
The U.S. Market is Estimated at US$7.5 Million While China is Forecast to Grow at 6.0% CAGR
The Lung Cancer Screening Software market in the U.S. is estimated at US$7.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Global Lung Cancer Screening Software Market - Revolutionizing Early Detection and Diagnosis
Why Is Lung Cancer Screening Software Gaining Popularity?
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with a high mortality rate due to late-stage detection. Early diagnosis significantly improves survival rates, and lung cancer screening software is emerging as a crucial tool in enhancing detection accuracy and efficiency. The adoption of artificial intelligence (AI) and machine learning (ML) in medical imaging is driving the market, as these technologies help radiologists and oncologists identify lung nodules with greater precision. Government initiatives and screening programs aimed at high-risk populations, such as long-term smokers, are further propelling the demand for advanced screening solutions. The increasing integration of lung cancer screening software into hospital radiology departments and telemedicine platforms is making early detection more accessible and effective.
How Are Innovations Enhancing the Performance of Lung Cancer Screening Software?
The integration of AI-driven algorithms and deep learning models is significantly improving the accuracy of lung cancer screening software. These technologies enhance image analysis by detecting even the smallest nodules, reducing false positives and false negatives in diagnosis. Cloud-based screening platforms and telemedicine integration are expanding access to screening services, particularly in remote and underserved areas. The adoption of predictive analytics is helping physicians assess patient risk factors and prioritize high-risk cases for further evaluation. Additionally, the combination of lung cancer screening software with electronic health records (EHRs) is streamlining workflow efficiency, allowing for real-time data analysis and automated reporting.
What Are the Key Market Drivers?
Several factors are fueling the growth of the lung cancer screening software market. The rising prevalence of lung cancer and the increasing emphasis on early detection are key drivers. Government regulations and healthcare policies supporting lung cancer screening programs, particularly in developed nations, are accelerating adoption rates. The growing use of AI and automation in healthcare, along with increasing investments in digital health technologies, is further boosting the demand for sophisticated screening solutions. Additionally, the expansion of cloud-based medical imaging platforms and the increasing collaboration between software developers and healthcare providers are contributing to market growth.
What Challenges and Future Opportunities Exist?
Despite its potential, the lung cancer screening software market faces challenges such as high implementation costs, data privacy concerns, and interoperability issues with existing healthcare IT systems. Resistance from traditional radiologists who rely on manual image analysis may also slow down adoption. However, the growing acceptance of AI-assisted diagnostics, the development of more cost-effective cloud-based solutions, and advancements in regulatory compliance are creating significant opportunities. Future growth in the market will be driven by AI-powered real-time diagnosis, personalized screening protocols based on genetic and lifestyle factors, and the integration of lung cancer screening software into mobile health applications.
SCOPE OF STUDY:
The report analyzes the Lung Cancer Screening Software market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Single Segment
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 36 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.